Strict Regulation and Enforcement of Therapeutic E-Cigarette Products in Australia

Aug.06.2024
Strict Regulation and Enforcement of Therapeutic E-Cigarette Products in Australia
Australian TGA director, Prof Tony Lawler, emphasizes quality and safety regulations for therapeutic e-cigarette products.

According to a report by Pledge Times on August 6, Professor Tony Lawler, director of the Therapeutic Goods Administration (TGA) in Australia, emphasized during a meeting that the Therapeutic Goods Order 100 will ensure the quality and safety of therapeutic e-cigarette products. He acknowledged the challenges pharmacists face when evaluating unregistered products, and highlighted that regulatory reforms and enhanced border control measures help manage imported products. These products must be regulated as therapeutic goods, which is why they are not sold in retail environments.


He assured pharmaceutical professionals that the responsibility for ensuring the safety of e-cigarette products to the public does not solely rest on community pharmacists.


He also emphasized strict control over the concentration, flavor, and color of e-cigarettes, and pointed out that e-cigarettes are being withdrawn from retail environments to ensure they are managed by health professionals. He stressed that only e-cigarette products that meet TGA standards can be imported and sold in Australia.


According to reports, the Therapeutic Goods Administration (TGA) and the Queensland Department of Health recently conducted a two-day joint enforcement operation, seizing over 10,000 nicotine pouches and hundreds of illegal e-cigarette products. The confiscated e-cigarettes are suspected of violating the new commercial possession laws under the Therapeutic Goods and Other Legislation Amendment (E-cigarette Reform) Act, which came into effect on July 1st. These laws prohibit Australian retailers from providing any e-cigarette products, even with a prescription, and prohibit the possession of e-cigarettes in retail premises.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
Spain’s PSOE files motion to curb vaping and nicotine pouches, restricting sales channels and banning online sales
Spain’s PSOE files motion to curb vaping and nicotine pouches, restricting sales channels and banning online sales
Spain’s Socialist Party (PSOE) has registered a non-legislative motion (PNL) in Congress seeking to curb the use of vapes and nicotine pouches by restricting sales to authorised channels and banning sales online and in non-specialist shops. The proposal says the current “lack of control” in commercialisation facilitates tax evasion and breaches existing health and environmental rules.
Mar.03 by 2FIRSTS.ai
Global Forum on Nicotine 2026 to explore why prohibition of safer nicotine products risks, and does not protect, public health
Global Forum on Nicotine 2026 to explore why prohibition of safer nicotine products risks, and does not protect, public health
Mar.12
IMF Article Sets Out Three Principles: Cover All Harmful Products, Match Tax Rates to Harm, Improve Cross-Border Coordination
IMF Article Sets Out Three Principles: Cover All Harmful Products, Match Tax Rates to Harm, Improve Cross-Border Coordination
A March 2026 article in Finance & Development, “Taxing Harmful Habits,” argues that taxes on harmful products such as tobacco, alcohol and sugary drinks should better reflect the health harm they cause. The authors propose three principles: capture all harmful products, align tax rates with health harm, and strengthen cross-border coordination to reduce evasion and smuggling.
Mar.24 by 2FIRSTS.ai
Kenya’s BAT Kenya resumes Velo nicotine pouches after citing regulatory clarity
Kenya’s BAT Kenya resumes Velo nicotine pouches after citing regulatory clarity
BAT Kenya says it has resumed sales of Velo oral nicotine pouches after receiving regulatory clarity, reinforcing its push into non-combustible products as cigarette consumption falls.The company reported a 10% drop in turnover in 2025, with revenue closing at KSh23.2 billion (about $178.64 million), largely attributed to the growing presence of illegal tobacco products.
Mar.03 by 2FIRSTS.ai
South Africa health department agrees to exempt smokeless and non-combustible products from tobacco control bill
South Africa health department agrees to exempt smokeless and non-combustible products from tobacco control bill
At a parliamentary committee meeting in South Africa, Health Minister Aaron Motsoaledi said the health department has agreed to exempt non-combustible and smokeless products — including chewing tobacco, snus, nicotine pouches and e-cigarettes — from the Tobacco Products and Electronic Delivery Systems Control Bill. The department is prepared, at this stage, to exempt them from packaging and labelling requirements except for misleading or false claims.
Mar.06 by 2FIRSTS.ai